TNFα in isolated perfusion systems: Success in the limb, developments for the liver credits, debits and future perspectives

Anticancer Research

Volumn 18, Issue 5 D, 1998, Pages 3899-3905

  Eggermont, Alexander M M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Carcinoma; Clinical; Isolated perfusion; Limb; Liposomes; Liver; Melanoma; Preclinical; Sarcoma; TNF ; Tumor models

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOSTATIC AGENT; FLOXURIDINE; FLUOROURACIL; GAMMA INTERFERON; LIPOSOME; MELPHALAN; NITRIC OXIDE SYNTHASE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA;

ANTINEOPLASTIC ACTIVITY; BALLOON CATHETER; CANCER RESEARCH; CARCINOMA; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG RESEARCH; HUMAN; HYPOXIA; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY PERFUSION; LIMB PERFUSION; LIMB SALVAGE; LIVER CANCER; LIVER PERFUSION; LUNG PERFUSION; MELANOMA; NONHUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; SOFT TISSUE SARCOMA;

ANIMALS; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; DRUG SCREENING ASSAYS, ANTITUMOR; EXTREMITIES; FORECASTING; HUMANS; LIVER NEOPLASMS; SOFT TISSUE NEOPLASMS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0031744292     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (80)

1. Carswell EA, Old LJ, Kassel RL et al: An endotoxin induced serum factor that causes necrosis of tumors. Proc Nat Acad Sci USA 72: 3666-3370, 1975.
2. Sugarman BJ, Aggarwal BB, Hass PE, et al: Recombinant tumor necrosis factor-alpha: effects on proliferation of normal and transformed cells in vitro. Science 230: 943-945, 1985.
3. Fajardo LF, Kwan HH, Kowalski J, Prionas SD and Allison AC: Dual role of Tumor Necrosis Factor-aπ in angiogenesis. Am J Pathol 140: 539-544, 1992.
4. Sato N, Goto T, Haranaka K, Satomi N, Nariuchi H, Mano-Hirano Y, Sawasaki Y: Actions of TNF on cultured vascular endothelial cells: morphological modulation, growth inhibition and cytotoxicity. J Natl Cancer Inst 76: 1113-1117, 1987.
5. Watanabe N, Niitsu Y, Umeno H, Sone H, Neda H, Yamauchi N, Maeda M, Urushizaki I: Toxic effect of TNF on tumor vasculature in mice. Cancer Res 49: 2179-2183, 1988.
6. Bloksma N, van de Wiel PA, Kuper CF, Hofhuis FMA: Multiple facets of induction of tumor necrosis. Ann Inst Pasteur/Immunol 139: 294-97, 1988.
7. Nawroth P, Handley D, Matsueda G, DeWaal G, Gerlach H, Blohm D, Stern D: TNF/Cachectin-induced intravascular fibrin formation in Meth-A fibrosarcomas. J Exp Med 168: 637-647, 1988.
8. Chapman PB, Lester TJ, Casper ES: Clinical pharmacology of recombinant tumor necrosis factor in patients with advanced disease. J Clin Oncol 5: 1942-1951, 1987.
9. Blick M, Sherwin SA, Rosenblum M, Gutterman J: Phase I study of recombinant tumor necrosis factor in cancer patients. Cancer Res 476: 2986-2989, 1987.
10. Selby P, Hobbs S, Viner C: Tumor necrosis factor in man: Clinical and biological observations. Br J Cancer 56: 803-808, 1987.
11. Gamm H, Lindemann A, Mertelsmann R, Hermann F: Phase I trial of recombinant tumor necrosis factor-alpha in patients with advanced malignancy. Eur J Cancer 7: 856-863, 1991.
12. Benckhuijsen C, Kroon BBR, Van Geel AN, Wieberdink J: Regional perfusion treatment with melphalan for melanoma in a limb: Evaluation of drug kinetics. Eur J Surg Oncol 14: 157-163, 1988.
13. Asher A, Mule JJ, Reichert CM, Shiloni E, Rosenberg SA: Studies on the anti-tumor effciacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo. J Immunol 138: 963-974, 1987.
14. Lienard D, Ewalenko, Delmotte JJ, Renard N, and Lejeune FJ: High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 10: 50-62, 1992.
15. Lejeune FJ, Lienard D, Leyvraz S, and Mirimanoff RO: Regional therapy of melanoma. Eur J Cancer 29A: 606-612, 1993.
16. Eggermont AMM, Lienard D, Schraffordt Koops H, Kroon BBR, Rosenkaimer F, Klaase JM, Schmitz RIM, Lejeune FJ: High dose TNFα in isolation perfusion of the limb: highly effective treatment for melanoma in transit metastases and unresectable sarcomas. Reg Cancer Treat 8: 32-36, 1995.
17. Eggermont AMM, Schraffordt Koops H, Lienard D, Kroon BBR, van Geel AN, Hoekstra HJ, and Lejeune FJ: Isolated limb perfusion with high-dose tumor necrosis factor-α in combination with interferon-g and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. J Clin Oncol 14: 2653-2665, 1996.
18. Eggermont AMM, Schraffordt Koops H, Klausner J, Kroon BBR, Schlag PM, Lienard D, Van Geel AN, Hoekstra HJ, Meller I, Nieweg OE, Kettelhack C, Ben-Ari G, Pector JC, Lejeune FJ: Isolated Limb Perfusion with tumor necrosis factor-an and melphalan in 186 patients with locally advanced extremity sarcomas: the cumulative multicenter european experience. Ann Surgery 224: 756-765, 1996.
19. Eggermont AMM, Schraffordt Koops H, Klausner JM, Lienard D, Kroon BBR, Schlag PM, Ben-Ari G, and Lejeune FJ: Isolation Limb Perfusion with Tumor Necrosis Factor Alpha and Chemotherapy for Advanced Soft Tissue Sarcomas. Sem Oncology 24: 547-555, 1997.
20. Eggermont AMM, Schraffordt Koops H, Lienard D, Lejeune FJ, Oukerk M: Angiographic observations before and after high dose TNF isolated limb perfusion in patients with extremity soft tissue sarcomas. Eur J Surg Oncol 20: 323, 1994.
21. Sijens PE, Eggermont AMM, Van Dijk P, Oudkerk M: P magnetic resonance spectroscopy as predictor for clinical response in human extremity sarcomas treated by single dose TNFα + melphalan isolated limb perfusion. NMR in Biomedicine 18: 215-224, 1995.
22. Renard N, Lienard D, Lespagnard L, Eggermont AMM, Heimann R, Lejeune FJ: Early endothelium activation and polymorphonuclear cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular high-dose tumour necrosis factor alpha (TNFα). Int J Cancer 57: 656-663, 1994.
23. Renard N, Nooijen PTGA, Schalkwijk L, DeWaal RMW, Eggermont AMM, Lienard D, Kroon BBR, Lejeune FJ, Ruiter DJ: VWF release and platelet aggregation in human melanoma after perfusion with TNFα. J Pathol 176: 279-287, 1995.
24. Nooijen PTGA, Eggermont AMM, Verbeek MM, Schalkwijk L, DeWaal RWM, Ruiter DJ: Transient induction of E-selectin expression following TNF-based isolated limb perfusion in melanoma and sarcoma patients is not tumor specific. J Immunother 19: 33-44, 1996.
25. Kort WJ, Zondervan PE, Hulsman LOM, Wijma IM, Westbroek DL: Incidence of spontaneous tumors in a group of retired breeder female Brown Norway rats. J Natl Cancer Inst 72: 709-713, 1984.
26. Barendsen, GW, Janse HC: Differences in effectiveness of combined treatments with ionizing radiation and vinblastine, evaluated for experimental sarcomas and squamous cell carcinomas in rats. Int J Radiat Oncol Biol Phys 4: 95-102, 1978.
27. Manusama ER, Durante NMC, Marquet RL, Eggermont AMM: Ischemia promotes the antitumor effect of tumor necrosis factor alpha (TNFa) in isolated limb perfusion in the rat. Reg Cancer Treat 7: 155-159, 1994.
28. Manusama ER, Nooijen PTGA, Stavast J, Durante NMC, Marquet RL, Eggermont AMM: Synergistic antitumour effect of recombinant human tumour necrosis factor a with melphalan in isolated limb perfusion in the rat. Br J Surg 83: 551-555, 1996.
29. Manusama ER, Stavast J, Durante NMC, Marquet RL, Eggermont AMM: Isolated limb perfusion in a rat osteosarcoma model: a new anti-tumour approach. Eur J Surg Oncol 22: 152-157, 1996.
30. Nooijen PTGA, Manusama ER, Eggermont AMM, Schalkwijk L, Stavast J, marquet RL, de Waal RMW, Eggermont AMM, Ruiter DJ:Synergistic effects of TNFα and melphalan in an isolated limb perfusion model of rat sarcoma: a histopathological, immunohistochemical and electromicroscopical study. Br J Cancer 74: 1908-1915, 1996.
31. Posner M, Lienard D, Lejeune FJ, Rosenfelder D, Kirkwood JM: Hyperthermic isolated limb perfusion (HILP) with tumor necrosis factor (TNF) alone for metastatic intransit melanoma. Proc Am Soc Clin Oncol 13: 1351(abstract), 1994.
32. DeWilt JHW, Manusama ER, Ten Hagen TLM, Van Tiel AS, Eggermont AMM: Requirements for optimal antitumor effects with isolated limb perfusion with TNF + Melphalan in sarcoma bearing rats. Ann Surg, 1998;in press
33. Brouckaert PGG, Leroux-Rouls GG, Guisez Y Tavernier J, Fiers W: In vivo anti-tumor activity of recombinant human and murine TNF, alone and in combination with IFN-gamma on a syngeneic murine melanoma. Int J Cancer 38: 763-769, 1986.
34. Manusama ER, DeWilt JHW, Van Tiel SA, TenHagen TLM, Eggermont AMM: The role of Interferon-gamma in TNF-base isolated limb perfusions in BN175 sarcoma bearing rats. (Submitted)
35. Manusama ER, Nooijen PTGA, Stavast J, DeWilt JHW, Marquet RL, Eggermont AMM: Assessment of the role of neutrophils on the antitumor effect of TNFα in an in vivo isolated limb perfusion model in sarcoma bearing Brown Norway rats. J Surg Res 75: in press, 1998.
36. Manusama ER, Durante NMC, Marquet RL, Eggermont AMM: Nitric Oxide inhibition enhances the antitumor effects of TNFα in an isolated limb perfusion (ILP) model in the rat. Eur J Surg Res 27(S1): 79, 1995.
37. Prograbniak HW, Witt CJ, Terrill R, Pass H: Isolated lung perfusion with tumor necrosis factor: a swine model in preparation of human trials. Ann Thorac Surg 57: 1477-83, 1994.
38. Fraker DL, Alexander HR, Thom AK: Use of tumor necrosis factor in isolated hepatic perfusion. Circulatory Shock 44: 45-50, 1994.
39. Vries de MR, Borel Rinkes IHM, Wiggers T, Jonker AM, Weijers-Hille MJ, Eggermont AMM: Hyperthermic isolated hepatic perfusion with TNFα with and without melphalan in pigs. Eur J Surg Res 27(S1): 81(abstract), 1995.
40. Veen van de AH, Manusama ER, Kampen van CA, Durante NMC, Marquet RL, Eggermont AMM: Tumor Necrosis Factor-α (TNFα) in isolated kidney perfusions in rats: toxicity and antitumor effects. Eur J Surg Oncol 20: 404-405, 1994.
41. London WT: Primary hepatocellular carcinoma. Etiology, pathogenesis, and prevention. Hum Pathol 12: 1085-1097, 1981.
42. Okuda K: Early recognition of hepatocellular carcinoma. Hepatology 6: 729-738, 1986.
43. Nagasue N, Yukaya H, Hamada T: The natural history of hepatocellular carcinoma. A study of 100 untreated cases. Cancer 54: 1461-1465, 1984.
44. Sugarbaker PH: In: Priciples of cancer treatment, ed. DeVita VT, Hellman S, Rosenberg SA, Lippincott etc, New York. p795.
45. Foster JH, Berman MM: Solid liver tumors. In: Major problems in clinical surgery. ed. Ebert P, Philadelphia. WB Saunders. 1977: 1-342.
46. Steele G, Ravikumar TS: Resection of hepatic metastases from colorectal cancer. Biologic perspective. Ann Surg 210: 127-138, 1989.
47. Kemeny N: The systemic chemotherapy of hepatic metastases. Semin Oncol 10: 148-155, 1983.
48. Colins JM: Pharmacologic rationale for regional drug delivery. J Clin Oncol 2: 498-504, 1984.
49. Breedis C, Young C: The blood supply of neoplasms in the liver. Am. J Pathol 30: 969, 1954.
50. Sigurdson ER, Ridge JA, Kemeny N: Tumor and liver drug uptake following hepatic artery and portal vein infusion. J Clin One 5: 1936-1840, 1987.
51. Kemeny N, Schneider A: Regional treatment of hepatic metastases and hepatocellular carcinoma. Curr Probl Cancer 13: 197-283, 1989.
52. MAGIC: Reappraisel of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. J Nat Cancer Inst 88: 252-258, 1996.
53. Allen-Mersh TG, Earlam S, Fordy C, Abrams K, Houghton J: Quality oflife and survival with contiunous hepatic-artery floxuridine infusion for colorectal liver metastases. Lancet 344: 1255-60, 1994.
54. Aigner KR, Walther H, Tonn JC, Link KH, Schwemmle R: Die isolierte Leberperfusion mit 5-Fluorouracil (5-FU) beim Menschen. Chirurg, 53: 571, 1982.
55. Skibba JL, Almagro KA, Condon RE, Petroff RJA: A technique for isolation perfusion of the canine liver with survival. J Surg Res 34: 123, 1983.
56. Van de Velde CJH, de Brauw LM, Sugarbaker PH, Tranberg KG: Hepatic arterial infusion chemotherapy: rationale, results, credits and debits, in: Progress in Surgery of the liver, Pancreas and Biliary System. Bengmark, S. (ed), Martinus Nijhoff: Dordrecht, 1987, 163.
57. Marinelli A, van de Velde CJH, Kuppen PJK, Franken HCM, Souverijn JHM, Eggermont AMM: A comparative study of isolated liver perfusion versus hepatic artery infusion with mitomycin C in rats. Br J Cancer 62: 891-896, 1990.
58. De Brauw LM, Marinelli A, van de Velde CJH, Hermans J, Tjaden UR, Erkelens C, de Bruyn EA: Pharmacological evaluation of experimental isolated liver perfusion and hepatic artery infusion with 5-Fluorouracil. Cancer Res 51: 1694-1700, 1991.
59. Aigner KR: Isolated liver perfusion: 5-year results. Reg. Cancer Treat 1: 11-20, 1988.
60. Vahrmeyer A, Marinelli A Van Dierendonck JH, Van de Velde CJH: Clinical and experimental studies on isolated liver perfusion with high dosed alkylating agents. Reg Cancer Treatment 8: 25-31, 1995.
61. Aigner KR: Aortic stopflow infusion (ASI) and hypoxic abdominal perfusion (HAP) for disseminated bulky peritoneal carcinomatosis -rationale and technique. Reg Cancer Treat 6: 3, 1993.
62. Aigner KR, Kaevel K: Pelvic stopflow infusion (PSI) and hypoxic pelvic perfusion (HPP) with mitomycin and melphalan for recurrent rectal cancer. Reg Cancer Treat 7: 6-11, 1994.
63. Thompson JF, Liu M, Watson LD, Sheldon DM, Stephen MS, Storey DW, Kam PCA: A percutaneous aortic "stop-flow" infusion technique for regional cytotoxic therapy of the abdomen and pelvis. Reg Cancer Treat 7: 202-207, 1994.
64. Turk PS, Belliveau JF, Darnowski JW, Wanebo HJ: Isolated pelvic perfusion for unresectable cancer using a balloon occlusion technique. Arch Surg 128: 533-539, 1993.
65. Wanebo HJ, Chung MA, Levy AI, Turk PS, Vezeridis MP, Belliveau JF: Preoperative therapy for advanced pelvic malignancy by isolated pelvic perfusion with the balloon-occlusion technique. Ann Surg Oncol 3: 295-303, 1996.
66. Borel Rinkes IHM, De Vries MR, Jonker AM, Swaak AJG, Hack EC, Wiggers T, Eggermont AMM: Isolated hepatic perfusion in the pig with TNF-α with and without melphalan. Br J Cancer 75: 1447-1453, 1997.
67. IJken van MGA, Bruijn de EA, Boeck de G, Hagen ten TLM, Sijp van der JRM, Eggermont AMM: Isolated Hypoxic Hepatic Perfusion with Tumor Necrosis Factor-alpha, melphalan and mitomycin C using ballooncatheter techniques: a pharmacokinetic study in pigs. In press Ann Surg 1998.
68. Vries de MR, Borel Rinkes IHM, Hack CE, Wiggers Th, Van de Velde CJH, Kuppen PJK, Eggermont AMM: Isolated hepatic perfusion with TNFα and Melphalan: local and systemic effects on secondary cytokine release, coagulation and fibrinolysis. Eur J Surg Res 27(S1): 109, 1995.
69. Vries de MR, Borel Rinkes IHM, Buurman WA, Wiggers Th, VandeVelde CJH, Eggermont AMM: Soluble TNFα receptors induction by isolated hepatic perfusion with TNFα and melphalan. Eur J Surg Res 27(S1): 108(abstract), 1995.
70. de Vries MR, Borel Rinkes IHM, Van de Velde CJH, Tollenaer RAEM, Vahrmeijer A, Wiggers T, Kuppen Pjk, Eggermont AMM: Isolated hepatic perfusion with tumor necrosis factor-α (TNFα) and melphalan. Rec Results Cancer Res 147: in press, 1998.
71. Fraker DL, Alexander HR, Thom AK: Use of tumor necrosis factor in isolated hepatic perfusion. Cire Shock 44: 45-50, 1994.
72. Alexander HR, Baartlett DL, Libutti SK Fraker D, Rosenberg SA: Isolated Hepatic Perfusion With Tumor Necrosis Factoran (TNFα) and Melphalan for unresectable cancers confined to the liver. J Clin Oncol 16 in press,.
73. Vaupel P, Kallinowski F, Okunieff P: Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res 49: 6449-6465, 1989.
74. Teicher BA, Lazo JS, Sartorelli AC: Classification of antineoplastic agents by their selective toxicities towards oxygenated and hypoxic tumor cells. Cancer Res 41: 73-81, 1981.
75. Veen van der AH, ten Hagen TLM, Van Tiel ST, Seynhaeve ALB, Eggermont AMM: Biodistribution of liposomal-TNF in the BN 175 rat sarcoma model. Int J Cancer in press, 1998.
76. Veen van der AH, ten Hagen TLM, Marquet RL, Eggermont AMM: Treatment of solid limb tumors with liposome-encapsulated Tumor Necrosis Factor-aπ in the rat. Proc Am Assoc Cancer Res 37: 483, 1996.
77. Gatanaga T, Noguchi K, Tanabe Y, Inagawa H, Soma G-I, Mizuno D: Antitumor effect of systemic administration of novel recombinant tumor necrosis factor (rTNF-S) with Less toxicity than conventional rTNFα in vivo. J Biol Resp Modif 8: 278-286, 1989.
78. Lodato RF, Feig B, Akimaru K, Soma G-I, Kloostergaard J: Hemodynamic evaluation of recombinant human tumor necrosis factor (TNF)-a, TNF-SAM2 and liposomal TNF-SAM2 in an anesthetized dog model. J Immunotherapy 17: 19-29, 1995.
79. Kuroda K, Miyata K, Shikama H, Kawagoe T, Nishimura K, Takeda K, Sakae N, Sakae N, Kato M: Novel muteins of human tumor necrosis factor with potent antitumor activity and less lethal toxicity in mice. Int J Cancer 63: 152-157, 1995.
80. DeWilt JHW, Soma G-I, Seynhaeve ALB, Van Tiel ST, TenHagen TLM, Eggermont AMM: Isolated limb perfusion using TNF-SAM2 in combination with doxorubicin and melphalan in rats. Eur J Surg Oncol 24: 202, 1998.